HC Wainwright Brokers Increase Earnings Estimates for Savara

Savara Inc (NASDAQ:SVRA) – Equities researchers at HC Wainwright increased their FY2024 earnings per share estimates for shares of Savara in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.46) per share for the year, up from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Other equities research analysts also recently issued reports about the stock. JMP Securities reiterated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Down 1.8 %

NASDAQ:SVRA opened at $3.19 on Friday. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a twelve month low of $3.09 and a twelve month high of $5.70. The company has a market cap of $525.08 million, a PE ratio of -7.60 and a beta of 1.02. The company’s 50 day moving average is $3.93 and its two-hundred day moving average is $4.21.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11).

Institutional Investors Weigh In On Savara

Several hedge funds have recently added to or reduced their stakes in SVRA. BNP Paribas Financial Markets raised its stake in shares of Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock valued at $366,000 after buying an additional 35,269 shares during the last quarter. Swiss National Bank purchased a new position in Savara during the first quarter valued at approximately $732,000. ProShare Advisors LLC lifted its holdings in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after acquiring an additional 2,114 shares during the period. Vanguard Group Inc. boosted its position in Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after purchasing an additional 148,673 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co acquired a new stake in shares of Savara during the 1st quarter worth approximately $35,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.